Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matias A Avila

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Cancers|September 26, 2020
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and TreatmentMaria L Martínez-Chantar, Matias A Avila, Shelly C Lu
Gut|February 24, 2019
Messenger RNA therapy for rare genetic metabolic diseasesPedro Berraondo, Paolo G V Martini, Matias A Avila, et al.
Seminars in Immunology|July 30, 2025
Epigenetic mechanisms in HCC immune landscape: Therapeutic implicationsMaite G Fernandez-Barrena, Iker Uriarte, Pablo Sarobe, et al.
Seminars in Cell & Developmental Biology|April 4, 2019
Chromatin dynamics during liver regenerationMaria Arechederra, Carmen Berasain, Matias A Avila, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2002
S-Adenosylmethionine: a control switch that regulates liver functionJose M Mato, Fernando J Corrales, Shelly C Lu, et al.
JHEP Reports : Innovation in Hepatology|November 2, 2020
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the icebergMaite G Fernández-Barrena, María Arechederra, Leticia Colyn, et al.
Gut|September 23, 2025
Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applicationsBarbara Bueloni, Maite G Fernandez-Barrena, Esteban Fiore, et al.
The American Journal of Pathology|August 5, 2024
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic SignificanceRocio I R Macias, Hiroaki Kanzaki, Carmen Berasain, et al.
Gut|February 23, 2025
RNA-based therapies in liver metabolic diseasesAntonio Fontanellas, Pedro Berraondo, Francesco Urigo, et al.
The Journal of Experimental Medicine|December 21, 2006
Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioningMaria Iñiguez, Carmen Berasain, Eduardo Martinez-Ansó, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Cancers|September 26, 2020
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and TreatmentMaria L Martínez-Chantar, Matias A Avila, Shelly C Lu
Gut|February 24, 2019
Messenger RNA therapy for rare genetic metabolic diseasesPedro Berraondo, Paolo G V Martini, Matias A Avila, et al.
Seminars in Immunology|July 30, 2025
Epigenetic mechanisms in HCC immune landscape: Therapeutic implicationsMaite G Fernandez-Barrena, Iker Uriarte, Pablo Sarobe, et al.
Seminars in Cell & Developmental Biology|April 4, 2019
Chromatin dynamics during liver regenerationMaria Arechederra, Carmen Berasain, Matias A Avila, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2002
S-Adenosylmethionine: a control switch that regulates liver functionJose M Mato, Fernando J Corrales, Shelly C Lu, et al.
JHEP Reports : Innovation in Hepatology|November 2, 2020
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the icebergMaite G Fernández-Barrena, María Arechederra, Leticia Colyn, et al.
Gut|September 23, 2025
Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applicationsBarbara Bueloni, Maite G Fernandez-Barrena, Esteban Fiore, et al.
The American Journal of Pathology|August 5, 2024
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic SignificanceRocio I R Macias, Hiroaki Kanzaki, Carmen Berasain, et al.
Gut|February 23, 2025
RNA-based therapies in liver metabolic diseasesAntonio Fontanellas, Pedro Berraondo, Francesco Urigo, et al.
The Journal of Experimental Medicine|December 21, 2006
Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioningMaria Iñiguez, Carmen Berasain, Eduardo Martinez-Ansó, et al.
Pageof 8